Browsing Tag
clinical trials
129 posts
Sona Nanotech set to launch first human trial of its gold nanoparticle cancer therapy
Sona Nanotech receives ethics approval to begin first-in-human melanoma trial using gold nanorod-based hyperthermia therapy. Patient dosing to start soon.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.
Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases
Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development
AtomVie Global Radiopharma signs agreement with TerraPower Isotopes to secure actinium-225 supply, aiming to advance CDMO-based cancer radiotherapies.